Composition
1 coated tablet contains:
Active ingredient:
memantine gilrochloride 10 mg;
Auxiliary substances:
lactose,
MCC,
colloidal silicon dioxide,
talc,
magnesium stearate,
shell:
methacrylic acid copolymer,
sodium lauryl sulfate,
talc.
Pharmacological action
Pharmacodynamics
Being a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, it has a modulating effect on the glutamatergic system. Regulates ion transport, blocks calcium channels, normalizes the membrane potential, and improves the process of nerve impulse transmission. Improves cognitive processes, increases daily activity.
Pharmacokinetics
After oral use, Acatinol Memantine is rapidly and completely absorbed. The maximum concentration in the blood plasma is reached within 2-6 hours. No accumulation of the drug was observed in normal renal function. Elimination proceeds in two phases. The elimination half-life is 4-9 hours in the first phase and 40-65 hours in the second phase. It is excreted in the urine.
Indications
Alzheimer’s type dementia, vascular dementia, mixed dementia of all degrees of severity.
Contraindications
- individual hypersensitivity to the drug Akatinol Memantine;
- severe renal dysfunction;
- pregnancy;
- breastfeeding;
- children under 18 years of age (due to insufficient data).
With caution:
- thyrotoxicosis;
- epilepsy;
- convulsions (including in the anamnesis);
- myocardial infarction;
- heart failure.
Side effects
Adverse reactions are classified according to clinical manifestations (according to the lesion of certain organ systems) and frequency of occurrence:
From the body as a whole-common side effects
Often Headache
Rarely Fatigue
Infections Rarely Fungal infections
Mental disorders Often Drowsiness
Rarely Confusion
Rarely Hallucinations
Frequency not established
Psychotic reactions
Disorders of the cardiovascular system
Rarely Hypertension
Rarely Venous thrombosis / thromboembolism
Gastrointestinal disorders Often Constipation
Rarely Nausea, vomiting
Frequency not established Pancreatitis
Central and peripheral nervous system disorders
Often Dizziness
Rarely Gait disorder
Very rarely, Convulsive
Hallucinations have been observed, mainly in patients with Alzheimer’s disease at the stage of severe dementia.
There are isolated reports of these adverse reactions occurring when the drug is used in clinical practice (data obtained after the drug became commercially available).
Interaction
When used concomitantly with L-dopa preparations, dopamine agonists, and anticholinergic agents, the effect of the latter may be enhanced.
When used concomitantly with barbiturates, neuroleptics, the effect of the latter may decrease.
When used together, it can change (increase or decrease) the effect of dantrolene or baclofen, so the dosage of drugs should be selected individually. Concomitant use with amantadine, ketamine, and dexamethorphan should be avoided.
It is possible to increase plasma levels of cimetidine, procainamide, kinidine, kinine and nicotine when taken simultaneously with memantine. It is possible to reduce the level of hydrochlorothiazide when taken simultaneously with memantine.
How to take, course of use and dosage
Inside, while eating. The dosage regimen is set individually. It is recommended to start treatment with the minimum effective dose.
Adults with dementia during the 1st week of therapy — at a dose of 5 mg / day, the 2nd week-at a dose of 10 mg/day, the 3rd week-at a dose of 15-20 mg/day. If necessary, a further weekly dose increase of 10 mg is possible until the daily dose of 30 mg is reached.
The optimal dose is achieved gradually, with an increase in the dose every week.
Overdose
Symptoms: increased severity of side effects.
Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.
Special instructions
With caution prescribed for epilepsy, patients with thyrotoxicosis. The optimal dose is achieved gradually, with a weekly increase.
Patients with moderate to severe Alzheimer’s disease usually have impaired ability to drive vehicles and manage complex mechanisms.
In addition, memantine can cause changes in the reaction rate, so patients receiving outpatient treatment should take special care when driving vehicles or operating mechanisms.
Form of production
Film-coated tablets
Storage conditions
At a temperature not exceeding 25 °C
Shelf life
4 years
Active ingredient
Memantine
Conditions of release from pharmacies
By prescription
Dosage form
Tablets
Description
For adults as directed by your doctor
Indications
Alzheimer’s disease, Stroke Effects, Acquired Dementia, Concussion and other traumatic brain injuries, Alcoholism
Best price for Acathinol Memantine, pills 20mg, 28pcs in our online pharmacy!
Side effects of Acathinol Memantine, pills 20mg, 28pcs.
Reviews
There are no reviews yet